Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1The decision is supported by the ...
Well, what we do know as individuals get older, they want the same things. They want to be able to stay in their homes. They ...
A novel way for governments and corporations to shape AI’s impact is to create advance market commitments that create ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback